Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
Esophageal Squamous Cell Carcinoma
DRUG: Afatinib|DRUG: Toripalimab
Objective response rate, Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST)., From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
Duration of response, Measure of time from first response to disease progression or death, Up to 2 years|Disease control rate, Percentage of patients who achieve partial response (PR) or complete response (CR) or stable disease (SD) based on Response Evaluation Criteria In Solid Tumors (RECIST)., From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.|Incidence of Treatment-Related Adverse Events, Number of adverse events., Until 30 days after the last treatment|Progression free survival, Measure of time from study treatment to disease progression or death., Up to 2 years|Overall survival, Measure of time from study treatment to patient's death or lost to follow-up., Up to 2 years
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.